ACADIA PHARMACEUTICALS INC. (ACAD) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 1.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 100.98M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $1.14B | $100.98M | (m) |
| 2026-03-31 | (m) | $1.10B | $93.40M | (m) |
| 2025-12-31 | (m) | $1.07B | $89.00M | (m) |
| 2025-09-30 | (m) | $1.05B | $84.58M | (m) |
| 2025-06-30 | (m) | $1.02B | $81.79M | (m) |
| 2025-03-31 | (m) | $996.28M | $79.28M | (m) |
| 2024-12-31 | (m) | $957.80M | $81.84M | (m) |
| 2024-09-30 | (m) | $929.24M | $77.93M | (m) |
| 2024-06-30 | (m) | $890.53M | $73.69M | (m) |
| 2024-03-31 | (m) | $813.81M | $62.92M | (m) |
| 2023-12-31 | $684.80M | $726.44M | $41.64M | 94.27% |
| 2023-09-30 | (m) | $631.89M | $26.16M | (m) |
| 2023-06-30 | (m) | $550.90M | $13.68M | (m) |
| 2023-03-31 | (m) | $520.23M | $8.88M | (m) |
| 2022-12-31 | $507.07M | $517.24M | $10.17M | 98.03% |
| 2022-09-30 | (m) | $511.50M | $10.20M | (m) |
| 2022-06-30 | (m) | $512.40M | $11.75M | (m) |
| 2022-03-31 | (m) | $493.06M | $11.61M | (m) |
| 2021-12-31 | $473.30M | $484.14M | $10.84M | 97.76% |
| 2021-09-30 | (m) | $474.39M | $10.91M | (m) |
| 2021-06-30 | (m) | $463.36M | $9.22M | (m) |
| 2021-03-31 | (m) | $458.24M | $9.60M | (m) |
| 2020-12-31 | $431.54M | $441.75M | $10.21M | 97.69% |
| 2020-12-30 | $431.54M | $441.75M | (m) | 97.69% |
| 2020-09-30 | (m) | $419.07M | $10.72M | (m) |
| 2020-06-30 | (m) | $393.08M | $11.13M | (m) |
| 2020-03-31 | (m) | $366.19M | $11.19M | (m) |
| 2019-12-31 | $327.73M | $339.08M | $11.34M | 96.65% |
| 2019-09-30 | (m) | $300.32M | (m) | (m) |
| 2019-06-30 | (m) | $264.04M | (m) | (m) |
| 2019-03-31 | (m) | $237.90M | (m) | (m) |
| 2018-12-31 | $211.43M | $223.81M | (m) | 94.47% |
| 2018-09-30 | (m) | $207.80M | (m) | (m) |
| 2018-06-30 | (m) | $185.07M | (m) | (m) |
| 2018-03-31 | (m) | $158.48M | (m) | (m) |
| 2017-12-31 | $115.82M | $124.90M | (m) | 92.73% |
| 2017-09-30 | (m) | $93.30M | (m) | (m) |
| 2017-06-30 | (m) | $62.99M | (m) | (m) |
| 2017-03-31 | (m) | $32.61M | (m) | (m) |
| 2016-12-31 | $14.25M | $17.33M | (m) | 82.23% |
| 2016-09-30 | (m) | $5.39M | (m) | (m) |
| 2016-06-30 | (m) | $157.00K | (m) | (m) |
| 2016-03-31 | (m) | $61.00K | (m) | (m) |
| 2015-12-31 | (m) | $61.00K | (m) | (m) |
| 2015-09-30 | (m) | $92.00K | (m) | (m) |
| 2015-06-30 | (m) | $67.00K | (m) | (m) |
| 2015-03-31 | (m) | $94.00K | (m) | (m) |
| 2014-12-31 | (m) | $120.00K | (m) | (m) |
| 2014-09-30 | (m) | $109.00K | (m) | (m) |
| 2014-06-30 | (m) | $335.00K | (m) | (m) |
| 2014-03-31 | (m) | $758.00K | (m) | (m) |
| 2013-12-31 | (m) | $1.15M | (m) | (m) |
| 2013-09-30 | (m) | $1.49M | (m) | (m) |
| 2013-06-30 | (m) | $4.73M | (m) | (m) |
| 2013-03-31 | (m) | $4.87M | (m) | (m) |
| 2012-12-31 | (m) | $4.91M | (m) | (m) |
| 2012-09-30 | (m) | $5.12M | (m) | (m) |
| 2012-06-30 | (m) | $2.22M | (m) | (m) |
| 2012-03-31 | (m) | $2.08M | (m) | (m) |
| 2011-12-31 | (m) | $2.07M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $42.13M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $6.40M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |